In an interview with PharmaShots, James E. Brown, President, CEO, and Director of Durect shared his views on the clinical data of DUR-928 in P-1b trial for NASH and P-I trial for Hepatic Impairment
Shots:
The P-Ib trial evaluates DUR-928 (50/150/600mg for 4wks.) in 65 patients with NASH with stage 1-3 fibrosis which showed improvement…
